{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Antigène CD63 : Questions médicales les plus fréquentes",
"headline": "Antigène CD63 : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Antigène CD63 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-02-06",
"dateModified": "2025-05-01",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Antigène CD63"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Protéines du transport vésiculaire",
"url": "https://questionsmedicales.fr/mesh/D033921",
"about": {
"@type": "MedicalCondition",
"name": "Protéines du transport vésiculaire",
"code": {
"@type": "MedicalCode",
"code": "D033921",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.543.990"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Antigène CD63",
"alternateName": "Tetraspanin 30",
"code": {
"@type": "MedicalCode",
"code": "D060149",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Thorsten Lang",
"url": "https://questionsmedicales.fr/author/Thorsten%20Lang",
"affiliation": {
"@type": "Organization",
"name": "Department of Membrane Biochemistry, Life & Medical Sciences (LIMES) Institute, University of Bonn, Carl-Troll-Straße 31, 53115 Bonn, Germany. Electronic address: thorsten.lang@uni-bonn.de."
}
},
{
"@type": "Person",
"name": "Annemiek B van Spriel",
"url": "https://questionsmedicales.fr/author/Annemiek%20B%20van%20Spriel",
"affiliation": {
"@type": "Organization",
"name": "Department of Tumor Immunology and."
}
},
{
"@type": "Person",
"name": "Jana Jankovičová",
"url": "https://questionsmedicales.fr/author/Jana%20Jankovi%C4%8Dov%C3%A1",
"affiliation": {
"@type": "Organization",
"name": "Laboratory of Reproductive Physiology, Center of Biosciences, Institute of Animal Biochemistry and Genetics, Slovak Academy of Sciences, Bratislava, Slovak Republic."
}
},
{
"@type": "Person",
"name": "Petra Sečová",
"url": "https://questionsmedicales.fr/author/Petra%20Se%C4%8Dov%C3%A1",
"affiliation": {
"@type": "Organization",
"name": "Laboratory of Reproductive Physiology, Center of Biosciences, Institute of Animal Biochemistry and Genetics, Slovak Academy of Sciences, Bratislava, Slovak Republic."
}
},
{
"@type": "Person",
"name": "Jana Antalíková",
"url": "https://questionsmedicales.fr/author/Jana%20Antal%C3%ADkov%C3%A1",
"affiliation": {
"@type": "Organization",
"name": "Laboratory of Reproductive Physiology, Center of Biosciences, Institute of Animal Biochemistry and Genetics, Slovak Academy of Sciences, Bratislava, Slovak Republic. jana.antalikova@savba.sk."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Prediction of visual field progression in glaucoma: existing methods and artificial intelligence.",
"datePublished": "2023-08-04",
"url": "https://questionsmedicales.fr/article/37540325",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s10384-023-01009-3"
}
},
{
"@type": "ScholarlyArticle",
"name": "A Novel Visual Field Screening Program for Glaucoma With a Head-Mounted Perimeter.",
"datePublished": "2023-02-28",
"url": "https://questionsmedicales.fr/article/36847662",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/IJG.0000000000002199"
}
},
{
"@type": "ScholarlyArticle",
"name": "Teleglaucoma Using a New Smartphone-Based Tool for Visual Field Assessment.",
"datePublished": "2022-11-29",
"url": "https://questionsmedicales.fr/article/36730078",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/IJG.0000000000002153"
}
},
{
"@type": "ScholarlyArticle",
"name": "Differences in eccentricity for sound-induced flash illusion in four visual fields.",
"datePublished": "2022-11-17",
"url": "https://questionsmedicales.fr/article/36397675",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1177/03010066221136670"
}
},
{
"@type": "ScholarlyArticle",
"name": "Iridotomy to slow progression of visual field loss in angle-closure glaucoma.",
"datePublished": "2023-01-09",
"url": "https://questionsmedicales.fr/article/36621864",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/14651858.CD012270.pub3"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides aminés, peptides et protéines",
"item": "https://questionsmedicales.fr/mesh/D000602"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines",
"item": "https://questionsmedicales.fr/mesh/D011506"
},
{
"@type": "ListItem",
"position": 4,
"name": "Protéines membranaires",
"item": "https://questionsmedicales.fr/mesh/D008565"
},
{
"@type": "ListItem",
"position": 5,
"name": "Protéines du transport vésiculaire",
"item": "https://questionsmedicales.fr/mesh/D033921"
},
{
"@type": "ListItem",
"position": 6,
"name": "Antigène CD63",
"item": "https://questionsmedicales.fr/mesh/D060149"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Antigène CD63 - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Antigène CD63",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-07",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Antigène CD63",
"description": "Comment détecte-t-on l'antigène CD63 ?\nQuels tests sont utilisés pour le CD63 ?\nLe CD63 est-il un marqueur de maladie ?\nQuelle est l'importance du CD63 dans le diagnostic ?\nLe CD63 est-il spécifique à certaines cellules ?",
"url": "https://questionsmedicales.fr/mesh/D060149?mesh_terms=Visual+Fields&page=4#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Antigène CD63",
"description": "Quels symptômes sont liés à une activation du CD63 ?\nLe CD63 est-il associé à des maladies spécifiques ?\nQuels signes cliniques peuvent indiquer un problème avec le CD63 ?\nLe CD63 influence-t-il la réponse immunitaire ?\nPeut-on mesurer le CD63 dans le sang ?",
"url": "https://questionsmedicales.fr/mesh/D060149?mesh_terms=Visual+Fields&page=4#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Antigène CD63",
"description": "Comment prévenir les réactions liées au CD63 ?\nY a-t-il des mesures préventives pour les maladies liées au CD63 ?\nLe dépistage précoce est-il utile pour le CD63 ?\nLes vaccinations aident-elles à prévenir les problèmes liés au CD63 ?\nL'éducation des patients est-elle importante pour le CD63 ?",
"url": "https://questionsmedicales.fr/mesh/D060149?mesh_terms=Visual+Fields&page=4#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Antigène CD63",
"description": "Comment traiter une réaction liée au CD63 ?\nLe CD63 est-il une cible thérapeutique ?\nQuels médicaments affectent le CD63 ?\nLe CD63 est-il impliqué dans des traitements anticancéreux ?\nY a-t-il des traitements spécifiques pour le CD63 ?",
"url": "https://questionsmedicales.fr/mesh/D060149?mesh_terms=Visual+Fields&page=4#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Antigène CD63",
"description": "Quelles complications peuvent survenir avec le CD63 ?\nLe CD63 est-il lié à des complications auto-immunes ?\nComment les complications liées au CD63 sont-elles gérées ?\nLe CD63 peut-il aggraver d'autres conditions médicales ?\nY a-t-il des risques à long terme liés au CD63 ?",
"url": "https://questionsmedicales.fr/mesh/D060149?mesh_terms=Visual+Fields&page=4#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Antigène CD63",
"description": "Quels sont les facteurs de risque pour l'activation du CD63 ?\nL'âge influence-t-il le CD63 ?\nLe stress affecte-t-il le CD63 ?\nY a-t-il des prédispositions génétiques pour le CD63 ?\nL'environnement joue-t-il un rôle dans l'activation du CD63 ?",
"url": "https://questionsmedicales.fr/mesh/D060149?mesh_terms=Visual+Fields&page=4#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment détecte-t-on l'antigène CD63 ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'antigène CD63 est détecté par des techniques comme la cytométrie en flux."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour le CD63 ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests immunologiques comme l'immunofluorescence peuvent être utilisés."
}
},
{
"@type": "Question",
"name": "Le CD63 est-il un marqueur de maladie ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le CD63 peut être un marqueur dans certaines pathologies, notamment les allergies."
}
},
{
"@type": "Question",
"name": "Quelle est l'importance du CD63 dans le diagnostic ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il aide à identifier certaines cellules immunitaires et leur activation."
}
},
{
"@type": "Question",
"name": "Le CD63 est-il spécifique à certaines cellules ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il est principalement exprimé sur les mastocytes et les plaquettes."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont liés à une activation du CD63 ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une activation excessive peut entraîner des réactions allergiques ou inflammatoires."
}
},
{
"@type": "Question",
"name": "Le CD63 est-il associé à des maladies spécifiques ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il est souvent associé à des maladies allergiques et auto-immunes."
}
},
{
"@type": "Question",
"name": "Quels signes cliniques peuvent indiquer un problème avec le CD63 ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes comme l'urticaire ou l'anaphylaxie peuvent être observés."
}
},
{
"@type": "Question",
"name": "Le CD63 influence-t-il la réponse immunitaire ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il joue un rôle clé dans la modulation de la réponse immunitaire."
}
},
{
"@type": "Question",
"name": "Peut-on mesurer le CD63 dans le sang ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des niveaux de CD63 peuvent être mesurés dans le sérum pour évaluer l'activation."
}
},
{
"@type": "Question",
"name": "Comment prévenir les réactions liées au CD63 ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter les allergènes connus peut aider à prévenir les réactions liées au CD63."
}
},
{
"@type": "Question",
"name": "Y a-t-il des mesures préventives pour les maladies liées au CD63 ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des stratégies de gestion des allergies peuvent réduire les risques de réactions."
}
},
{
"@type": "Question",
"name": "Le dépistage précoce est-il utile pour le CD63 ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un dépistage précoce peut aider à identifier les risques d'allergies."
}
},
{
"@type": "Question",
"name": "Les vaccinations aident-elles à prévenir les problèmes liés au CD63 ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines vaccinations peuvent réduire le risque de maladies allergiques."
}
},
{
"@type": "Question",
"name": "L'éducation des patients est-elle importante pour le CD63 ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, informer les patients sur les allergies peut aider à prévenir les réactions."
}
},
{
"@type": "Question",
"name": "Comment traiter une réaction liée au CD63 ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antihistaminiques sont souvent utilisés pour traiter les réactions allergiques."
}
},
{
"@type": "Question",
"name": "Le CD63 est-il une cible thérapeutique ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des thérapies ciblant le CD63 sont en développement pour certaines maladies."
}
},
{
"@type": "Question",
"name": "Quels médicaments affectent le CD63 ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des médicaments immunosuppresseurs peuvent influencer l'expression du CD63."
}
},
{
"@type": "Question",
"name": "Le CD63 est-il impliqué dans des traitements anticancéreux ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il est étudié comme un potentiel marqueur pour des thérapies anticancéreuses."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements spécifiques pour le CD63 ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'existe pas de traitements spécifiques ciblant uniquement le CD63."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec le CD63 ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications comme des chocs anaphylactiques peuvent survenir en cas d'activation excessive."
}
},
{
"@type": "Question",
"name": "Le CD63 est-il lié à des complications auto-immunes ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une activation anormale du CD63 peut contribuer à des maladies auto-immunes."
}
},
{
"@type": "Question",
"name": "Comment les complications liées au CD63 sont-elles gérées ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles sont gérées par des traitements d'urgence et des soins médicaux appropriés."
}
},
{
"@type": "Question",
"name": "Le CD63 peut-il aggraver d'autres conditions médicales ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une activation excessive peut aggraver des conditions comme l'asthme."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques à long terme liés au CD63 ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des risques à long terme incluent des maladies chroniques si non gérées correctement."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour l'activation du CD63 ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antécédents d'allergies et d'expositions environnementales sont des facteurs de risque."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le CD63 ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines populations, comme les enfants, peuvent être plus sensibles aux allergies."
}
},
{
"@type": "Question",
"name": "Le stress affecte-t-il le CD63 ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress peut exacerber les réactions allergiques et l'activation du CD63."
}
},
{
"@type": "Question",
"name": "Y a-t-il des prédispositions génétiques pour le CD63 ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des facteurs génétiques peuvent influencer la réponse immunitaire et le CD63."
}
},
{
"@type": "Question",
"name": "L'environnement joue-t-il un rôle dans l'activation du CD63 ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des facteurs environnementaux comme la pollution peuvent augmenter le risque."
}
}
]
}
]
}
Timely treatment is essential in the management of glaucoma. However, subjective assessment of visual field (VF) progression is not recommended, because it can be unreliable. There are two types of ar...
A novel visual field screening program with a head-mounted perimeter 'imo' could detect glaucoma at all stages in a short time with high accuracy....
The present study aimed to examine the accuracy and availability of a novel glaucoma visual field screening program using a head-mounted visual perimeter 'imo.'...
Eyes of 76 non-glaucoma participants and 92 glaucoma patients were examined. All patients underwent visual field tests using the Humphrey Visual Field Analyzer (30-2 or 24-2 Swedish Interactive Thresh...
The sensitivity, specificity, positive predictive value, and negative predictive value of the visual field screening program were 76%-100%, 91%-100%, 86%-89%, and 79%-100%, respectively. The visual fi...
Visual field screening using a head-mounted perimeter 'imo' detected glaucoma at all stages in a short time with high accuracy....
COVID-19 underlines the importance of telemedical diagnostics. The smartphone-based campimetry (Sb-C) is a newly developed digital application allowing visual field testing using a head-mounted device...
Sb-C is a newly developed tool for functional ophthalmic diagnosis. This study aimed to examine the comparability of the Sb-C and Octopus 900 to ensure ophthalmological care in times of social distanc...
Total 93 eyes were included in the study. After an ophthalmological examination, the visual field was tested by the Octopus program G1 and by the smartphone-based campimeter. The Sb-C was performed us...
The group comprised 48 women and 45 men (mean age: 62.52±12.2 y) including 19 controls, 17 patients with ocular hypertension, 11 preperimetric glaucomas, and 46 perimetric glaucomas. The mean sensitiv...
With some technical adjustments, the Sb-C shows promise for screening glaucoma and monitoring disease progression remotely from an ophthalmologic clinic....
A sound-induced flash illusion (SiFI) is a multisensory illusion dominated by auditory stimuli, in which the individual perceives that the number of visual flashes is equal to the number of auditory s...
Primary angle-closure glaucoma is a type of glaucoma associated with a physically obstructed anterior chamber angle. For example, contact between the iris and lens at the pupillary margin creates a pu...
To assess the effects of iridotomy compared with no iridotomy for primary angle-closure glaucoma, primary angle-closure, and primary angle-closure suspect....
We searched the Cochrane Central Register of Controlled Trials (CENTRAL; 2021, Issue 10), which contains the Cochrane Eyes and Vision Trials Register; MEDLINE Ovid; Embase Ovid; PubMed; LILACS; Clinic...
Randomized or quasi-randomized controlled trials that compared iridotomy with no iridotomy in primary angle-closure suspects, people with primary angle-closure, or people with primary angle-closure gl...
We used standard Cochrane methodology and assessed the certainty of the body of evidence for prespecified outcomes using the GRADE approach....
We identified four studies (3086 eyes of 1543 participants) that compared iridotomy with no iridotomy in participants (range of mean age 59.6 to 62.9 years) who were primary angle-closure suspects fro...
Individuals with homonymous visual field loss (HVFL) fail to perceive visual information that falls within the blind portions of their visual field. This places additional burden on memory to represen...
Functional gradients, in which response properties change gradually across the cortical surface, have been proposed as a key organising principle of the brain. However, the presence of these gradients...
Coordination of goal-directed behavior depends on the brain's ability to recover the locations of relevant objects in the world. In humans, the visual system encodes the spatial organization of sensor...
Contrast sensitivity (CS) is closely associated with vision-related quality of life in glaucoma patients. This cross-sectional study was performed to determine the relationship between CS and visual f...
Visual field loss is a common consequence of stroke and often precludes driving. However, legal visual requirements for drivers' licenses are largely without scientific basis....
This study aimed to examine the effects of different types of homonymous visual field loss after stroke on simulated driving....
Data on performance and safety from a traffic simulator test for 153 participants with withdrawn drivers' licenses due to visual field loss from stroke were retrospectively compared with data from 83 ...
Sixty-five percent of the stroke participants passed the simulator test (95% confidence interval, 57 to 72%). Younger patients were more successful than older. However, classification by neither type ...
In this large cohort, driver safety could not be predicted from the type of homonymous visual field loss. Even individuals with severe visual field loss might be safe drivers. Therefore, it seems reas...